Preclinical Evaluation of the Association of the Cyclin-Dependent Kinase 4/6 Inhibitor, Ribociclib, and Cetuximab in Squamous Cell Carcinoma of the Head and Neck

Preclinical Evaluation of the Association of the Cyclin-Dependent Kinase 4/6 Inhibitor, Ribociclib, and Cetuximab in Squamous Cell Carcinoma of the Head and Neck

Epidermal growth factor receptor (EGFR) overexpression is observed in 90% of human papillomavirus (HPV)-negative squamous cell carcinomas of the head and neck (SCCHN). Cell cycle pathway impairments resulting in cyclin-dependent kinase (CDK) 4 and 6 activation, are frequently observed in SCCHN. We i...

Full description

Bibliographic Details
Main Authors: Gabrielle van Caloen, Sandra Schmitz, Cédric van Marcke, Xavier Caignet, Antonella Mendola, Sébastien Pyr dit Ruys, Pierre P. Roger, Didier Vertommen, Jean-Pascal Machiels
Format: Article
Language:English
Published: MDPI AG 2021-03-01
Series:Cancers
Subjects:
squamous cell carcinoma of the head and neck
CDK4/6
ribociclib
cetuximab
retinoblastoma
resistance
Online Access:https://www.mdpi.com/2072-6694/13/6/1251

Internet

https://www.mdpi.com/2072-6694/13/6/1251

Similar Items